Is anti‐IL‐17 faster and anti‐IL‐23 better for psoriasis patients after adalimumab failure?
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | JEADV Clinical Practice |
| Online Access: | https://doi.org/10.1002/jvc2.306 |